NICE R&D cost request sets orphan drug precedent with Soliris guidance
This article was originally published in Scrip
Executive Summary
NICE, the health technology appraisal institute for England and Wales, has set a precedent for the way in which it plans to evaluate orphan drugs by asking Alexion to provide information on its R&D costs for Soliris (eculizumab). NICE says that it needs this information to justify the £57.8m a year cost to the NHS should the drug be recommended.